• Essali A, Al-Haj Haasan N, Li C, Rathbone J. (2009): Clozapine versus typical neuroleptic medication for schizophrenia., Cochrane Database Syst Rev.,  Jan 21;(1), Review.
  • Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 1988;24(1):62-7.
  • Kinros J, Reichenberg A, Frangou S. The neurodevelopmental theory of schizophrenia: evidence from studies of early onset cases. Isr J Psychiatry Relat Sci. 2010;47(2):110-7.
  • Mangalore R, Knapp M. Cost of schizophrenia in England. Ment Health Policy Econ. 2007 Mar;10(1):23-41.
  • Mortimer AM, Singh P, Shepherd CJ, Puthiryackal J. (2010): Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world., Clin Schizophr Relat Psychoses. Apr;4 (1):49-55.
  • Rössler W, Salize HJ, van Os J, Riecher-Rössler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005 Aug;15(4):399-409
  • The WHO World Health Report: new understanding, new hope, 2001, Geneva
  • Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009 Aug 22;374(9690):620-7.
  • Picchioni MM, Murray RM. Schizophrenia. BMJ. 2007 Jul 14;335(7610):91-5.
  • Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry. 2003 Jan;64(1):30-4.